
How Does Your Stool Smell If You or Your Child Has Rotavirus?
Loose and watery stools are a common symptom of rotavirus, which may also have a distinct, foul-smelling odor. Rotavirus stool may appear green, yellow, or brown in color.
Rotavirus is a virus that affects the digestive tract. It causes gastroenteritis, an infection of the gastrointestinal tract. It most commonly affects children up to 5 years old, but rotavirus can affect people of any age.
Diarrhea and vomiting are the main symptoms of rotavirus. These symptoms can lead to dehydration, especially in kids. If fluids aren't replaced or the illness lasts longer than 1 week, dehydration may become a medical emergency.
Although stool doesn't usually have a pleasant smell, research suggests that rotavirus stools in particular may have a distinct smell.
Learn more about what rotavirus stool smells like, other symptoms of rotavirus to look for, and what to do if you think you or your child has this virus.
What does rotavirus stool smell like?
Poop doesn't usually smell good, but stool from rotavirus may have a distinctly foul smell, akin to a slight sulfur or rotten egg smell.
A 1987 study found that rotavirus stools in children had a distinct smell. Many nurses were able to classify the underlying cause of diarrhea based on smell alone, which was more effective than changes in stool color or texture.
Researchers aren't exactly sure why rotavirus may cause stools to have a distinct, foul-smelling odor. But it may be due to the virus's effects on the gut microbiome, colon fluid, and levels of acids, fats, and sugars in the stool.
What color is stool with rotavirus?
Other rotavirus symptoms
Symptoms of rotavirus typically appear within 2 days of contracting the virus and may last up to 8 days. Along with foul-smelling stools, symptoms may include:
Persistent diarrhea and vomiting may lead to dehydration, which may become serious if left untreated.
When to get medical attention
It's important to get medical attention if you or a child has symptoms of severe dehydration or high fever.
In adults, these can include confusion and dizziness. In everyone, including babies and toddlers, signs and symptoms of severe dehydration may include:
lethargy
not responding or acting as they normally do (in babies and toddlers)
rapid heart rate or breathing
sunken eyes
irritability
high fever
excessive thirst
decreased urination (fewer wet diapers)
crying without tears
soft spot on the top of the baby's head
You should also connect with a doctor if you're vomiting is persistent and doesn't get better.
What other conditions cause foul-smelling diarrhea?
Many gastrointestinal conditions may cause foul-smelling diarrhea, including:
other infections, like norovirus
malabsorption
Crohn's disease
celiac disease
short bowel syndrome
pancreatitis
cystic fibrosis
Certain dietary changes, such as going on a high fiber diet, may also cause foul-smelling diarrhea.
How is rotavirus treated?
Most cases of rotavirus can be treated with at-home care. The best thing to do is to stay hydrated and let the virus run its course. This includes drinking lots of fluids.
In many cases, drinking water is OK, but make sure you're also replacing the electrolytes you lose through vomiting or diarrhea.
Electrolyte drinks like Pedialyte or Gatorade (for older children or adults) may be helpful, but consider limiting apple juice, as the sugar in it may worsen diarrhea.
If you or your child gets severely dehydrated, intravenous (IV) fluid rehydration in a hospital may be required. This involves injecting fluids directly into your bloodstream via a vein, usually in the arm.
In some cases, adults can take antidiarrheal medication to help relieve symptoms. But for children, it's best to speak with a pediatrician to discuss the best method of management, as they may not be able to take medications.
Other important things to do if you think you or your child has rotavirus include:
staying home to rest, since rotavirus is very contagious
washing your hands often
waiting to eat once the vomiting has stopped (usually after the first 24 hours)
Frequently asked questions
Can you prevent rotavirus from being transmitted?
Practicing good hand hygiene can help prevent rotavirus from being transmitted from one person to another. Wash your hands with soap for at least 20 seconds or use hand sanitizer frequently throughout the day.
It's especially important to wash your hands after changing diapers, caring for a sick child, and using the bathroom.
Children should also keep their hands out of their mouths as much as possible.
The best way to prevent rotavirus transmission is to make sure children get the rotavirus vaccine, which is part of routine childhood vaccinations.
Practicing good hand hygiene can help prevent rotavirus from being transmitted from one person to another. Wash your hands with soap for at least 20 seconds or use hand sanitizer frequently throughout the day.
It's especially important to wash your hands after changing diapers, caring for a sick child, and using the bathroom.
Children should also keep their hands out of their mouths as much as possible.
The best way to prevent rotavirus transmission is to make sure children get the rotavirus vaccine, which is part of routine childhood vaccinations.
Can adults get rotavirus?
Yes, people of any age can get rotavirus.
Yes, people of any age can get rotavirus.
How do doctors diagnose rotavirus?
Symptoms of rotavirus are similar to those of other gastrointestinal conditions, so doctors often look at symptoms and treat those rather than testing for rotavirus.
However, doctors will rule out any serious conditions, like appendicitis. They may also test for bacterial causes of symptoms. Bacterial infections can cause more severe illnesses and are sometimes treated with antibiotics.
Symptoms of rotavirus are similar to those of other gastrointestinal conditions, so doctors often look at symptoms and treat those rather than testing for rotavirus.
However, doctors will rule out any serious conditions, like appendicitis. They may also test for bacterial causes of symptoms. Bacterial infections can cause more severe illnesses and are sometimes treated with antibiotics.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
25 minutes ago
- Associated Press
Kennedy names 8 vaccine committee replacements, including COVID shot critic
NEW YORK (AP) — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. They include a scientist who researched mRNA vaccine technology and transformed into a conservative darling for his criticisms of COVID-19 vaccines, and a leading critic of pandemic-era lockdowns. Kennedy's decision to 'retire' the previous 17-member panel was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations. The new appointees to the Advisory Committee on Immunization Practices include Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to popularity during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19. He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots. He's even suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years. Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named. Kennedy made the announcement in a social media post on Wednesday. The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how Food and Drug Administration-cleared vaccines should be used. The CDC's final recommendations are widely heeded by doctors and determine the scope of vaccination programs. ___ Associated Press reporter Amanda Seitz contributed to this report. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.


Medscape
an hour ago
- Medscape
Taletrectinib Approved for NSCLC
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to


Bloomberg
an hour ago
- Bloomberg
RFK Jr. Picks Eight New Members of CDC Vaccine Panel
Health and Human Services Secretary Robert F. Kennedy Jr. announced on X the names of eight new members of an expert panel that advises the federal government on vaccine policy. Kennedy removed all 17 former members of the panel on Monday.